Factors of interrupting chemotherapy in patients with advanced non-small-cell lung cancer

BMC Research Notes

Volumn 3, Issue , 2010, Pages

  Belbaraka, Rhizlane ^a,b   Trédan, Olivier ^a   Ray Coquard, Isabelle ^a   Chvetzoff, Giselle ^a   Bajard, Agathe ^a   Pérol, David ^a   Ismaili, Nabil ^b   Ismaili, Mohammed ^c   Errihani, Hassan ^b   Bachelot, Thomas ^a   Rebattu, Paul ^a  

^a CENTRE LÉON BÉRARD   (France)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Morocco)

^c MOULAY ISMAIL UNIVERSITY   (Morocco)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954753209     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-3-164     Document Type: Article

References (18)

1. A systematic review of physicians' survival predictions in terminally ill cancer patients. P Glare K Virik M Jones M Hudson S Eychmuller J Simes, BMJ 2003 327 195 8 10.1136/bmj.327.7408.195 12881260
2. Model for Severe Anemia Requiring Red Blood Cell Transfusion After Cytotoxic Conventional Chemotherapy Regimens. I Ray-Coquard A Le Cesne MT Rubio J Mermet C Maugard A Ravaud, JCO 1999 17 2840 6
3. Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. I Ray-Coquard H Ghesquière T Bachelot C Borg P Biron C Sebban, Br J Cancer 2001 85 816 22 10.1054/bjoc.2001.2011 11556830
4. Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. T Bachelot I Ray-Coquard G Catimel C Ardiet JP Guastalla A Dumortier, Ann Oncol 2000 11 151 6 10.1023/A:1008368319526 10761748
5. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. T Bachelot I Ray-Coquard C Mentetrier-Caux M Rastkha A Duk JY Blay, Br J Cancer 2003 88 1721 26 10.1038/sj.bjc.6600956 12771987
6. Interleukin 6, Interleukin 10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6 from the Groupe Français d'Immunotherapie. S Negrier D Perol C Menetrier-Caux B Escudier M Pallardy A Ravaud, JCO 2004 22 2371 8 10.1200/JCO.2004.06.121 (Pubitemid 41115394)
7. CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. C Borg I Ray-Coquard I Philip G Clapisson N Bendrisse-Vermard C Menetrier-Caux, Cancer 2004 101 2675 80 10.1002/cncr.20688 15503313
8. Revisions in the international System for staging Lung Cancer. CF Mountain, Chest 1997 111 1710 7 10.1378/chest.111.6.1710 9187198
9. Prognostic value of histology in patients with non-small-cell lung cancer. A Charloux G Hedelin A Dietemann T Lfoundza N Roeslin G Pauli, Lung Cancer 1997 17 123 34 10.1016/S0169-5002(97)00655-7 9194032
10. Prognostic factors for survival in patients with inoperable lung cancer. KE Stanley, J Natl Cancer Inst 1980 65 25 32 6930515
11. Survival determinants in extensive stage non-small-cell lung cancer: the South West Oncology Group experience. KS Albain JJ Crowley M LeBlanc RB Livingston, JCO 1991 9 1618 26
12. Prognostic factors for patients with Advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation. N Takigawa Y Segawa M Okahara Y Maeda I Takata M Kataoka, Lung Cancer 1996 15 67 77 10.1016/0169-5002(96)00571-5 8865124
13. Prognostic factors in advanced non-small-cell lung cancer: analysis of Eastern Cooperative Oncology Group trials from 1981-1992. M Jiroutek D Johnson R Blum, et al. Proc Am Soc Clin Oncol 1998 17 461 (Abstr 1774)
14. Prognostic factors in non-small-cell lung cancer: a decade of progress. MD Brundage D Davies WJ Mackillop, Chest 2002 122 1037 57 10.1378/chest.122.3. 1037 12226051
15. Chemotherapeutic management of stage IV non-small-cell lung cancer American College of Chest Physicians. MA Socinski DE Morris GA Masters R Lilenbaum, Chest 2003 123 226S 43S 10.1378/chest.123.1-suppl.226S 12527582
16. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. J Crawford D Cella CS Cleeland PY Cremieux GD Demetri BJ Sarokhan, Cancer 2002 95 888 95 10.1002/cncr.10763 12209734
17. impact of haemoglobin levels in the outcome of cancers treated with chemotherapy. SJ Van Belle V Cocquyt, Oncol Hemato 2003 47 1 11
18. Survival Prediction of Terminally Ill Cancer Patients by Clinical Symptoms: Development of a Simple Indicator. Tatsuya Morita Junichi Tsunoda Satoshi Inoue Chihara Satoshi, JJCO 1999 29 156 9 10225699